Pier­is Phar­ma­ceut­ic­als wins award of ​“Pharma Trend – Image & Innov­a­tion Award”.

On Septem­ber 14, the win­ners of the ​“Most Innov­at­ive Product” award in the cat­egory Leap Innov­a­tions were announced at the ​“Pharma Trend — Image & Innov­a­tion Award”. For­my­con came out on top ahead of Ethris, with third place going to Pier­is. The three Munich-based com­pan­ies were each honored for the devel­op­ment of thera­peut­ics against COV­ID-19. In addi­tion, the win­ners of the ​“Golden Tab­let” were chosen and the Pharma Trend Rank­ing with the best phar­ma­ceut­ic­al com­pan­ies was published.

For the first time this year, ​“The Most Innov­at­ive Product®” was chosen in the cat­egory Leap Innov­a­tions in col­lab­or­a­tion with Bio^M. Com­pan­ies that receive fund­ing from the Ger­man Fed­er­al Min­istry of Edu­ca­tion and Research (BMBF) or the state of Bav­aria to devel­op COV­ID-19 ther­apies in 2021 were eli­gible to apply.

Pier­is Phar­ma­ceut­ic­als GmbH is a mem­ber of the Indus­tri­al Bio­tech­no­logy Cluster and took third place with ​“Inhal­able Antic­al­in® thera­peut­ics for the treat­ment of SARS-CoV­‑2 induced lung injury”. By way of back­ground: A sig­ni­fic­ant pro­por­tion of patients con­tin­ue to suf­fer from severe impair­ment of lung func­tion after acute COV­ID-19 dis­ease due to severe dam­age to lung tissue. 

Pier­is’ pro­ject aims to treat such fibrot­ic dam­age to lung tis­sue. The inhal­able Antic­al­in® drug can­did­ate PRS-220 binds with high affin­ity to the pro­tein Con­nect­ive Tis­sue Growth Factor (CTGF). In par­al­lel, PRS-220 is also being clin­ic­ally developed for the treat­ment of idiopath­ic pul­mon­ary fibrosis.